Phase 1 - TKM 080301 for Primary or Secondary Liver Cancer - Full Text View - ClinicalTrials.gov (ovariancolorectal/pancreas/gastric (stomach)/breast)

TKM 080301 for Primary or Secondary Liver Cancer - Full Text View - ClinicalTrials.gov

Colorectal Cancer With Hepatic Metastases
Pancreas Cancer With Hepatic Metastase
Gastric Cancer With Hepatic Metastase
Breast Cancer With Hepatic Metastase
Ovarian Cancer With Hepatic Metastase

TKM 080301 for Primary or Secondary Liver Cancer

This study is currently recruiting participants.

Verified February 2012 by National Institutes of Health Clinical Center (CC)

First Received on September 16, 2011.   Last Updated on March 9, 2012   History of Changes

Sponsor:	National Cancer Institute (NCI)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT01437007

  Purpose

Background:

Cancer in the liver can start in the liver (e.g., primary liver cancer or hepatocellular cancer) or spread to the liver from cancers in other parts of the body (e.g. colon, pancreas, gastric, breast, ovarian, esophageal cancers, cancer with metastases to the liver.) People who have tumors that can be removed by surgery live longer than those whose cancer cannot be removed. Chemotherapy can shrink some tumors in the liver, which also helps people to live longer, and sometimes chemotherapy can shrink tumors enough that they can be removed by surgery. However, most chemotherapy drugs do not work well on tumors in the liver. In this study we are testing a new drug, TKM-080301, given directly into the cancer blood supply in the liver circulation, to see if it will cause tumors to shrink.

Objectives:

- To test the safety and effectiveness of TKM-080301 for cancer in the liver that has not responded to standard treatments.